We scan new podcasts and send you the top 5 insights daily.
Early company creation can rely on small bets across many projects searching for a rare outlier like Moderna. In Series A and B rounds, ticket sizes are too large for spray-and-pray tactics, forcing investors to fund companies toward clear milestones within 18 to 24 months.
Investor sentiment has fundamentally changed. During the COVID era, investors funded good ideas. Now, they want to de-risk their investments as much as possible, often requiring solid Phase 1 and even compelling Phase 2 data before committing significant capital.
An analysis of 547 Series B deals reveals two-thirds return less than 2x. This data demonstrates that a "spray and pray" strategy fails at this stage. The cost of misses is too high, and being even slightly worse than average in your picks will result in a failed fund. Discipline and picking are paramount.
Unlike tech investing, where a single power-law outlier can return the entire fund, biotech wins are smaller in magnitude. This dynamic forces biotech VCs to prioritize a higher success rate across their portfolio rather than solely hunting for one massive unicorn.
In cautious markets, biotech VCs aren't writing smaller checks; they are committing to larger rounds structured in tranches. This guarantees future capital if milestones are met, reducing financing risk. Founders must now present a comprehensive path to clinical proof of concept, not just a development candidate, to secure these large commitments.
The current market prefers funding drugs for clinically validated targets, reducing 'biology risk'. However, this floods popular targets with dozens of competitors, creating immense 'commercial risk' where only one or two can truly succeed in a crowded field, a potentially worse gamble.
Veteran VC Edward Van Wezel notes a dramatic shift in biotech financing. Seed rounds that were once a few million and Series A rounds around €15-20M have both increased by nearly a factor of five. This inflation has reshaped the investor landscape and the capital strategy required to build a successful biotech company.
The primary operational difference between biotech and big pharma isn't just budget size, but how resource constraints force radical prioritization. The entire biotech organization must align on three or four critical, needle-moving goals tied to the next financing catalyst, a level of focus often diffused in larger companies.
While biotech cannot easily replicate tech's rapid iteration cycles due to high costs and long feedback loops, it can adopt the capital efficiency model of tech seed investing. The strategy is to kill flawed projects quickly and cheaply, ensuring that when you lose, you lose small.
Previously, biotechs could raise smaller rounds expecting a near-term IPO. With the IPO window shut, investors now prefer larger, milestone-based (tranched) financings to ensure companies are funded through significant clinical readouts and market uncertainty.
Contrary to traditional wisdom, the most challenging part of the venture market is now the crowded and overpriced Series A/B. The speaker argues for a barbell strategy: either take massive ownership (15-20%) at pre-seed or invest in de-risked, late-stage winners, avoiding the squeezed returns of the middle stages.